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as additional controls. Results: Responses to acetylcholine (Ach) and A23187 were 
improved with spironolactone (Table 1) while responses to (endothelium Independent) 
agonist nitroglycerin and phenylephrine remained unaltered (pk relsxation of 100 * 3 vs. 
100 * 3% and constriction of 103 r 22 vs. 108 * 19% in placebo vs. spironolactone 
respectively. 
Table 1. 
Ach 
Pk Relaxation(%) ED, 
A23187 
Pk Relaxation (%) ED,, 
LDLR” Placebo 67.3 * 8.1 7.5 * 0.21 74.8 + 2.6 7.4 * 0.1 
LDLR”. Spiro 103.8 * 6.4 7.6 * 0.10 92.0 + 2.5’ 7.6 * 0.4 
‘=pcO.Ol vs. placebo, 
Time to thrombosis was decreased with aldosterone infusion (13+2 vs. 23+2 minutes in 
controls, ~‘0.05 by ANOVA) while spironolactone administration prolonged time to 
thrombosis (28+2 vs. 23~2 minutes. ~~0.05 by ANOVA). 
Conclusion: MR antagonism improves endothelial function and attenuates thrombotic 
response to injury while aldosterone potentiates thrombotic response to injury. These 
findings indicate an emerging role for aldosterone receptor antagonists in atherosclero- 
sis. 
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Background: The presence of left atrial thrombus (LAT) in mitral stenosis pabents is a 
contraindication to percutaneous transvenaus mitral commlssurotomy (PTMC). Although 
resolution of LAT after long-term oral anticoagulant therapy has been documented, its 
short-term effect, which would be more clinically important, has been less clearly estab- 
lished. 
Objectives: To estimate the disappearance rate of documented LAT among candidates 
for PTMC who were treating with oral anticoagulation for 6 months and to determine its 
significant predictors. 
Design: Prospective cohort study 
Methods: Between August 1996 and February 2002, a total of 687 consecutive PTMC 
candidates underwent both transthoracic and multiplane transesophageal echocardio- 
graphic studies (TTE. TEE). Of these, 219 pabents demonstrated LAT by TEE and were 
given oral anticoagulation (INR 2.0 to 3.0). The fate of LAT was studied at 6 months 
using both TTE and TEE. 
Results: Among 219 PTMC candidates with LAT (mean age 39.6+7.4 years, range 19-62 
years; 73% females), complete resolution of LAT was demonstrated in 53 cases at the 
first 8th.month follow-up, with an overall disappearance rate of 24.2% (95%CI: 18.5% to 
29.9%). All 53 patients subsequently underwent successful PTMC. None of the cases, 
with LAT in the atrial body (n=27), had LAT resolution. Among the 168 patients whose 
LAT persisted, the LAT swe had nevertheless been reduced by approximately 20% from 
the baseline (p<O.OOi). By using multiple logistic regression analysis, the significant pre- 
dictors associated with LAT resolution included a NYHA Class of 1 or 2 (OR=ll.ll: 
95%Cl=3.23. 33 33), a LAT size cl.6 cm2 at the first study (16.87: 5.56, SO.OO), a fixed 
LAT (4.35: 1.49, 12.5), a left atial spontaneous echo contrast of less than or equal to 
Grade 1 (3.45: 1.20, lO.O), and an INR of more than or equal to 2.5 (19.53: 3.37, 113.16). 
Conclusions: About a quarter of PTMC candidates wth LAT could awd heart surgery by 
safely undergoing PTMC after 6 months of oral anticoagulant therapy as their LAT had 
disappeared. Less clinical severity, presenting as a small and fixed LAT, less grading of 
the left atrial spontaneous echo contrast, and a tolerance to high INR, could enhance 
such an outcome. 
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Physiologic release of tissue-type plasmmogen activator (t-PA) from the endothelium is 
critical for vascular homeostasis. and IS prostacyclln and nitric oxide-independent in 
humans. Prewously, we have suggested that endothellal-derived hyperpolarizing factor 
(EDHF) may play a role in t-PA release. EDHF promotes endothelial-dependent smooth 
muscle relaxation and hyperpolarization, and is believed to be a cytochrome P450 
(CYP450) metabolite of arachidonic acid (AA). Calcium-dependent potassium channel 
blockade with tetraethylamlne (TEA), apamin and charybdotoxin, or CYP450 Inhibition 
with miconazole, are Indwsct, but accepted methods of EDHF antagonism. In this study, 
we tested the hypothesis that thrombin-induced t-PA release is EDHF-dependent. 
Human mwovascular endothelial cells were Incubated in with 2mM sodium butyrate for 
24 hours. Cells were washed and Incubated for 30 minutes I” M199+0.03% albumin and 
inhibitors in triplicate. The cells were then stimulated with 10 U/ml thrombin or vehicle. 
Medium was harvested at multiple time intervals and t-PA antigen was measured by 
ELISA. As expected, in the presence and absence of ASA and L-NAME, thrombin trig- 
gered a significant Induction of t-PA release. TEA had no effect on t-PA release at any 
doses, nor did apamin and charybdotoxin. However, miconazole effectively inhibited 
thrombin-induced t-PA release in a dose-dependent manner (l&=8 nM). The AA epoxy- 
genase inhibitor MS-PPOY inhibited both constitutive and thrombin-induced release oft- 
PA I” a dose-dependent manner. These studies tndlcate that miconazole and MS-PPOH. 
but not potaswm channel blockade, inhibit thrombln-induced t-PA release in the pres- 
ence of ASA and L-NAME. While these methods of EDHF antagonism are indirect, we 
speculate EDHF induces t-PA release through a mechanism independent of calcium- 
dependent K+ channel actwation. 
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Background: Intraarterial thrombosis and arterial wall inflammation interactions could be 
responsible for the sharp increase in C-reactive protein (CRP) observed in acute core- 
nary syndromes. Thus, we tested the hypothesis that CRP increase in a model of acute 
comnary syndromes such as coronary angioplasty could be due to intraarterial thrombo- 
sis. 
Methods: One hundred twenty-five patients who underwent a camnary angioplasty pro- 
cedure at our cath lab were included. We excluded patients with inflammatory, metabolic 
or neoplastic diseases. Patients with post angioplasty CWMB elevation were also 
excluded. lnflammabon markers studied were: CRP, IL 6, IL-1 b. and plasma macrophage 
colony stimulating factor (MCSF). Blood samples were collected pre angioplasty, 24 and 
48 hours after the procedure. In 71 patients an eptifibatide perfusion was initiated imme- 
diately after the procedure, and continued for only 24 hours. The remaining 54 patients 
received standard antithrombotic therapy. 
Results: CRP figures are shown in the table. IL-6, IL-1 b and MCSF results will be pre- 
sented at the meetina: 
Conclusions: C-r&&e protein increase after coronary angioplasty was suppressed by 
eptifibatide. a svnthetic ceatide which is a selective blocker of the platelet GP Ilb-llla ._ ,, 
receptor with no known anti-inflammatory effects. Thus, it seems that CRP increase in 
acute coronary syndromes could be mostly due to intraarterial thrombosis. 
C-reactive Protein After PTCA 
n Pre-PTCA 24 h 48 h 
Eptifibatlde 71 0.76*1 .I5 0.69rl 1.14*1.13 
Control 54 0.52kO.52 1.08+0.99 1.47e1.38 
P “S pco.oo1 “S 
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Background: Human adipose tissue produces substantial amounts of plasminogen acti- 
vator inhlbitor type-l (PAI-l), an established risk factor for cardiovascular disease. Little 
is known about natural regulators of PAI- in human adipose tissue. Therefore, the 
present study examines the possible effect of angiotensin II, atrial natwretic peptide 
(ANP). C-type natriuretic peptlde (CNP), and B-type natriuretic peptide (BNP) on PAI- 
expression in human adipose tissue. 
Methods: Human preadipocytes in primary culture were exposed to selected concentra- 
tions of angiotensin II (IOOnM, lpM, IOpM, 1OOpM) as well as ANP, CNP, and BNP 
(IOnM, lOOnM, 1pM) in the presence and absence of transforming growth factor-beta. 
PAI- protein was measured by ELISA, total protein colorimetically, PAI- mRNA by light 
cycler RT-PCR. Parallel experiments were performed in primary cultures of in vitro differ- 
entiated human adipocytes and in human adipose tissue explants. 
Results: Incubation with angiotensin II up to unphysiological doses as high as 100wM did 
not have a significant effect on PAI- secretion in all cell types (n=3). However, ANP, 
CNP, and BNP reduced basal PAI- expression in the conditioned media by up to 
21%*5, 16%*6, and 44%*8 in preadipocytes (1x7, P<O.O5). Stimulation with TGF-beta 
resulted in a lo-fold increase of basal PAI- production (n=7, p<O.OOl). Under stimulated 
conditions ANP, CNP and BNP significantly suppressed PAI- levels by up to 25%i7, 
31%*8, 20%*8 (n=7, P<O.O5). In human adipocytes ANP downregulated TGF-beta 
Induced PAI-1 expression by up to 31%+9, CNP by up to 22%*12, and BNP by up to 
42%+13 (n=5, ~~0.05). Similar results were found I” human adipose tissue explants. 
Total protein quantification indicated persistent viability of cells. Quantification of PAI- 
mRNA suggested that regulation occured at the transcriptional level. 
Conclusions: Anglotensin II does not influence PAI- expression in human adipose tis- 
sue. In contrast, ANP, CNP, and BNP slgnlficantly reduce PAI- expression in all cell 
types. These observations suggest that natriuretic peptides may have an antithrombotic 
and antiatherogenic effect by being natural downregulators of PAI-1, 
